keyword
MENU ▼
Read by QxMD icon Read
search

radionuclide therapy

keyword
https://www.readbyqxmd.com/read/28211920/evaluation-of-acridine-orange-derivatives-as-dna-targeted-radiopharmaceuticals-for-auger-therapy-influence-of-the-radionuclide-and-distance-to-dna
#1
Edgar Pereira, Letícia do Quental, Elisa Palma, Maria Cristina Oliveira, Filipa Mendes, Paula Raposinho, Isabel Correia, João Lavrado, Salvatore Di Maria, Ana Belchior, Pedro Vaz, Isabel Santos, António Paulo
A new family of (99m)Tc(I)- tricarbonyl complexes and (125)I-heteroaromatic compounds bearing an acridine orange (AO) DNA targeting unit was evaluated for Auger therapy. Characterization of the DNA interaction, performed with the non-radioactive Re and (127)I congeners, confirmed that all compounds act as DNA intercalators. Both classes of compounds induce double strand breaks (DSB) in plasmid DNA but the extent of DNA damage is strongly dependent on the linker between the Auger emitter ((99m)Tc or (125)I) and the AO moiety...
February 13, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28203088/peptide-receptor-radionuclide-therapy-in-the-management-of-gastrointestinal-neuroendocrine-tumors-efficacy-profile-safety-and-quality-of-life
#2
REVIEW
Stefano Severi, Ilaria Grassi, Silvia Nicolini, Maddalena Sansovini, Alberto Bongiovanni, Giovanni Paganelli
Peptide receptor radionuclide therapy (PRRT), developed over the last two decades, is carried out using radiopharmaceuticals such as 90Y-DOTA-Tyr3-octreotide and 177Lu-DOTA-Tyr3-octreotate (177Lu-Dotatate). These radiocompounds are obtained by labeling a synthetic somatostatin analog with a β-emitting radioisotope. The compounds differ from each other in terms of their energetic features (due to the radionuclide) and peptide receptor affinity (due to the analog) but share the common characteristic of binding specific membrane somatostatin receptors that are (generally) overexpressed in neuroendocrine neoplasms (NENs) and their metastases...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28197764/new-frontiers-in-prostate-cancer-imaging-clinical-utility-of-prostate-specific-membrane-antigen-positron-emission-tomography
#3
REVIEW
Asim Afaq, Deepak Batura, Jamshed Bomanji
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway. Gallium-68-labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment. Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition...
February 14, 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28193502/development-of-a-preclinical-211-rn-211-at-generator-system-for-targeted-alpha-therapy-research-with-211-at
#4
Jason R Crawford, Hua Yang, Peter Kunz, D Scott Wilbur, Paul Schaffer, Thomas J Ruth
INTRODUCTION: The availability of (211)At for targeted alpha therapy research can be increased by the (211)Rn/(211)At generator system, whereby (211)At is produced by (211)Rn electron capture decay. This study demonstrated the feasibility of using generator-produced (211)At to label monoclonal antibody (BC8, anti-human CD45) for preclinical use, following isolation from the (207)Po contamination also produced by these generators (by (211)Rn α-decay). METHODS: (211)Rn was produced by (211)Fr electron capture decay following mass separated ion beam implantation and chemically isolated in liquid alkane hydrocarbon (dodecane)...
January 29, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/28189025/-211-rn-211-at-and-209-at-production-with-intense-mass-separated-fr-ion-beams-for-preclinical-211-at-based-%C3%AE-therapy-research
#5
Jason R Crawford, Peter Kunz, Hua Yang, Paul Schaffer, Thomas J Ruth
Mass-separated francium beams ((211)Fr or (213)Fr) were implanted into solid targets for producing (211)Rn (14.6h half-life) or (209)At (5.41h), in situ. (211)Rn was transferred to dodecane and isolated from contaminants, providing sources for (211)At (7.21h) production by (211)Rn decay (73%). (209)At was recovered with high radionuclidic purity in aqueous solutions, directly. These experiments demonstrated Fr beam implantations as a novel method for producing preclinical quantities of (211)Rn/(211)At (for therapy) and (209)At (for imaging)...
January 27, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28187040/infushield-a-shielded-enclosure-for-administering-therapeutic-radioisotope-treatments-using-standard-syringe-pumps
#6
Dominic P Rushforth, Brenda E Pratt, Sarah J Chittenden, Iain S Murray, Louise Causer, Matthew J Grey, Jonathan I Gear, Yong Du, Glenn D Flux
The administration of radionuclide therapies presents significant radiation protection challenges. The aim of this work was to develop a delivery system for intravenous radioisotope therapies to substantially moderate radiation exposures to staff and operators. A novel device (InfuShield) was designed and tested before being used clinically. The device consists of a shielded enclosure which contains the therapeutic activity and, through the hydraulic action of back-to-back syringes, allows the activity to be administered using a syringe pump external to the enclosure...
March 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28183041/an-automated-flow-system-incorporating-in-line-acid-dissolution-of-bismuth-metal-from-a-cyclotron-irradiated-target-assembly-for-use-in-the-isolation-of-astatine-211
#7
Matthew J O'Hara, Anthony J Krzysko, Cynthia M Niver, Samuel S Morrison, Stanley L Owsley, Donald K Hamlin, Eric F Dorman, D Scott Wilbur
Astatine-211 ((211)At) is a promising cyclotron-produced radionuclide being investigated for use in targeted alpha therapy. The wet chemical isolation of trace quantities of (211)At, produced within several grams of Bi metal deposited onto an aluminum cyclotron target assembly, involves a multi-step procedure. Because the (211)At isolation method is labor-intensive and complex, automation of the method is being developed to facilitate routine processing at the University of Washington and to make it easier to transfer the process to other institutions...
February 2, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#8
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28167827/utilizing-the-power-of-cerenkov-light-with-nanotechnology
#9
REVIEW
Travis M Shaffer, Edwin C Pratt, Jan Grimm
The characteristic blue glow of Cerenkov luminescence (CL) arises from the interaction between a charged particle travelling faster than the phase velocity of light and a dielectric medium, such as water or tissue. As CL emanates from a variety of sources, such as cosmic events, particle accelerators, nuclear reactors and clinical radionuclides, it has been used in applications such as particle detection, dosimetry, and medical imaging and therapy. The combination of CL and nanoparticles for biomedicine has improved diagnosis and therapy, especially in oncological research...
February 7, 2017: Nature Nanotechnology
https://www.readbyqxmd.com/read/28166370/peptide-receptor-radionuclide-treatment-and-131-i-mibg-in-the-management-of-patients-with-metastatic-progressive-phaeochromocytomas-and-paragangliomas
#10
Konstantinos Nastos, Vincent T F Cheung, Christos Toumpanakis, Shaunak Navalkissoor, Anne-Marie Quigley, Martyn Caplin, Bernard Khoo
BACKGROUND AND OBJECTIVES: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGLs) and phaeochromocytomas (PCCs). The aim of the present study is to retrospectively compare the therapeutic outcomes of these modalities in patients with progressive/metastatic PCCs and PGLs. METHODS: Patients with progressive/metastatic PGLs and PCCs that were subjected to radionuclide treatment in our department were retrieved from our department's database for the period 1998-2013...
February 6, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28166150/68ga-dota-tate-pet-ct-for-molecular-imaging-of-somatostatin-receptor-expression-in-metastasizing-chordoma-comparison-with-18f-fdg
#11
Thorsten Derlin, Jan M Sohns, Katja Hueper
Chordoma is a rare slow-growing neoplasm of neuroectodermal origin, which frequently recurs after removal and has the potential to metastasize. We present the case of a 53-year-old man with metastasizing chordoma who underwent F-FDG and Ga-DOTA-TATE PET/CT for restaging of disease and for evaluation of targeted radionuclide therapy potential. On both F-FDG and Ga-DOTA-TATE PET scans, increased tracer accumulation was observed in chordoma metastases. Besides the increased glucose metabolism in chordoma, this case highlights the potential of Ga-DOTA-TATE PET/CT for restaging of chordoma as well the option of targeted radionuclide therapy in this entity...
February 3, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28152910/choosing-wisely-in-oncology-are-we-ready-for-value-based-care
#12
Doug Blayney, Mohammad Jahanzeb, Pamela Kadlubek, August Knape, Merry Jennifer Markham, Trang Pham, Tracey L Evans
: 275 Background: The Choosing Wisely (CW) Campaign challenges patients, healthcare providers, and specialty disease societies to make better decisions about healthcare delivery. In 2012, Schnipper et al. published ASCO's Top Five List targeting overuse of medications, tests, and procedures that are costly and lack evidence. 1.) Do not use cancer-directed therapy for patients with low performance status (undocumented, 3 or 4). 2.) Do not use PET, CT and radionuclide bone scans in the staging of early prostate cancer...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28127694/accuracy-and-precision-assessment-for-activity-quantification-in-individualized-dosimetry-of-177-lu-dotatate-therapy
#13
Gwennaëlle Marin, Bruno Vanderlinden, Ioannis Karfis, Thomas Guiot, Zena Wimana, Patrick Flamen, Stefaan Vandenberghe
BACKGROUND: In order to obtain a reliable (177)Lu-DOTATATE therapy dosimetry, it is crucial to acquire accurate and precise activity measurements with the radionuclide calibrator, the SPECT/CT camera, and the NaI(Tl) well counter. The aim of this study was to determine, in a clinical context, the accuracy and the precision of their activity quantification over a range of activities and time. Ninety-three (177)Lu sources from the manufacturer were measured in the radionuclide calibrator over 2...
December 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/28123519/role-of-gambogic-acid-and-nai-131-in-a549-ddp-cells
#14
Jing Huang, Xiaoli Zhu, Huan Wang, Shuhua Han, Lu Liu, Yan Xie, Daozhen Chen, Qiang Zhang, Li Zhang, Yue Hu
Resistance to platinum in tumor tissue is a considerable barrier against effective lung cancer treatment. Radionuclide therapy is the primary adjuvant treatment, however, the toxic side effects limit its dosage in the clinical setting. Therefore, the present study aimed to determine whether an NaI(131) radiosensitizer could help reduce the toxic side effects of radionuclide therapy. In vitro experiments were conducted to determine whether NaI(131) can inhibit platinum resistance in A549/DDP cells, which are cisplatin-resistant non-small cell lung cancer cells, and whether gambogic acid (GA) is an effective NaI(131) radiosensitizer...
January 2017: Oncology Letters
https://www.readbyqxmd.com/read/28117023/an-overview-of-bioactive-peptides-for-in-vivo-imaging-and-therapy-in-human-diseases
#15
Anna Lucia Tornesello, Maria Lina Tornesello, Franco M Buonaguro
Radiolabeled peptides, designed to bind with high affinity receptors selectively expressed on cell membranes of different human tissues, represent valuable tools for in vivo imaging of several human diseases. Solid-phase peptide synthesis as well as availability of bifunctional chelating agents and prosthetic groups allows the production and radiolabeling of several peptide-based molecules which are useful to target specific receptors on different cancer types. Among them, octreotide and other analogues of somatostatin, vasoactive intestinal peptide, CCK analogues, bombesin, α-MSH analogues, neurotensin, exendin, RGD substance P, conjugated to appropriate chelators, such as DTPA, NOTA, DOTA or TETA, and radiolabeled with specific radionuclides, have already been translated into the clinical practice with remarkable sensitivity and diagnostic accurateness...
January 20, 2017: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/28116223/the-incorporation-of-radionuclides-after-wounding-by-a-dirty-bomb-the-impact-of-time-for-decorporation-efficacy-and-a-model-for-cases-of-disseminated-fragmentation-wounds
#16
Alexis Rump, Daniela Stricklin, Andreas Lamkowski, Stefan Eder, Michael Abend, Matthias Port
Objective: In the case of a terrorist attack by a "dirty bomb" there is a risk of internal contamination with radionuclides through inhalation and wounds. We studied the efficacy of a decorporation treatment depending on the initiation time and duration. Approach: Based on biokinetic models, we simulated the impact of different diethylenetriaminepentaacetic acid treatments on the committed effective dose after the incorporation of plutonium-239. Results: For the same level of radioactivity, the dose was higher after the fast absorption from the wound than after a slow invasion following inhalation...
January 1, 2017: Advances in Wound Care
https://www.readbyqxmd.com/read/28114710/-pet-ct-molecular-imaging-and-theranostics-for-radionuclide-therapy
#17
Thorsten Derlin, Frank M Bengel
No abstract text is available yet for this article.
January 2017: Pneumologie
https://www.readbyqxmd.com/read/28109634/the-american-college-of-radiology-and-the-american-brachytherapy-society-practice-parameter-for-the-performance-of-radionuclide-based-high-dose-rate-brachytherapy
#18
Beth A Erickson, Nathan H J Bittner, Manjeet Chadha, Firas Mourtada, D Jeffrey Demanes
Brachytherapy is a radiation therapy method in which radionuclide sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application. This practice parameter refers only to the use of radionuclides for brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. High-dose-rate (HDR) brachytherapy uses radionuclides such as iridium-192 at dose rates of 20 cGy per minute (12 Gy per hour) or more to a designated target point or volume...
January 2017: Brachytherapy
https://www.readbyqxmd.com/read/28109633/the-american-college-of-radiology-and-the-american-brachytherapy-society-practice-parameter-for-the-performance-of-low-dose-rate-brachytherapy
#19
Akila N Viswanathan, Beth A Erickson, Geoffrey S Ibbott, William Small, Patricia J Eifel
Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site. This practice parameter refers only to the use of radionuclide brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. Low-dose-rate (LDR) brachytherapy has traditionally been used for treating prostate, head and neck, breast, cervical, and endometrial cancers as well as obstructive bile duct, esophageal, or bronchial lesions...
January 2017: Brachytherapy
https://www.readbyqxmd.com/read/28106830/-188-re-v-nitrido-radiopharmaceuticals-for-radionuclide-therapy
#20
REVIEW
Alessandra Boschi, Petra Martini, Licia Uccelli
The favorable nuclear properties of rhenium-188 for therapeutic application are described, together with new methods for the preparation of high yield and stable (188)Re radiopharmaceuticals characterized by the presence of the nitride rhenium core in their final chemical structure. (188)Re is readily available from an (188)W/(188)Re generator system and a parallelism between the general synthetic procedures applied for the preparation of nitride technetium-99m and rhenium-188 theranostics radiopharmaceuticals is reported...
January 19, 2017: Pharmaceuticals
keyword
keyword
100899
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"